Skip Navigation


Japanese Journal of Clinical Oncology Advance Access originally published online on April 10, 2009
Japanese Journal of Clinical Oncology 2009 39(5):310-314; doi:10.1093/jjco/hyp022
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
39/5/310    most recent
hyp022v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Kai, F.
Right arrow Articles by Ozono, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kai, F.
Right arrow Articles by Ozono, S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


© The Author (2009). Published by Oxford University Press. All rights reserved

Efficacy of Adjuvant Interferon-alpha Therapy Following Curative Resection in Renal Cell Carcinoma: Before the Molecular Targeting Therapy Era

Fumitake Kai, Tatsuya Takayama, Takayuki Sugiyama, Hiroshi Furuse, Soichi Mugiya and Seiichiro Ozono

Department of Urology, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan

For reprints and all correspondence: Tatsuya Takayama, Department of Urology, Hamamatsu University School of Medicine, 1-20-1 Higashi-ku Handayama, Hamamatsu, Shizuoka 431-3192, Japan. E-mail: ttakayam{at}hama-med.ac.jp

Received November 6, 2008; accepted February 20, 2009

Objective: Although present treatment programs for renal cell carcinoma (RCC) typically involve molecular-targeting drugs, interferon-alpha (IFN-{alpha}) remains an important therapeutic drug for this cancer.

Methods: We evaluated the effect of adjuvant therapy in 508 patients with RCC following curative surgery. Patients were classified into one of the two categories based on the duration and the total dose of IFN-{alpha} treatment.

Results: Median follow-up time was 65.5 months. Overall survival rates at 5, 10, 15 and 20 years were 88.8%, 80.5%, 69.6% and 54.1%, respectively. Cause-specific survival rates at 5, 10, 15 and 20 years were 95.0%, 89.1%, 83.0% and 83.0%, respectively. Cox’s proportional hazard model revealed that C-reactive protein, T classification, histological grade and age were significantly independent factors indicative of a poor prognosis. Our examination of the 253 patients diagnosed as pT1-2N0M0 who underwent adjuvant IFN-{alpha} therapy following surgery found that the therapy was not significantly associated with either cause-specific or disease-free survival. With regard to effects of duration of therapy and total dose of IFN-{alpha}, patients with a total IFN-{alpha} exposure of ≥180 x 106 international units (IU) had a better prognosis than those exposed to <180 x 106 IU.

Conclusions: Adjuvant therapy using large doses of IFN-{alpha} may improve the prognosis of patients with RCC following curative resection, and the new possibility of IFN-{alpha} therapy merits further investigation.

Key Words: renal cell carcinoma • IFN-{alpha} • prognostic factor


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.